CEO Randall Lipps was paid $7,531,852 in fiscal year 2025, ↓ down 7.9% from fiscal year 2024, the 26th percentile of its disclosed peer group (SEC filing 0001104659-26-042631 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$7,531,852 ↓ Randall Lipps total, FY2025 | 26th CEO pay percentile vs peers | 70:1 CEO-to-median pay ratio | 96.02% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
OMCL's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Randall Lipps | $846,891 | $0 | $5,219,576 | $0 | $1,411,485 | $0 | $53,900 | $7,531,852 |
| Chairman, President and Chief Executive Officer | ||||||||
| Nnamdi Njoku | 645,000 | 0 | 2,456,275 | 0 | 860,000 | 0 | 43,839 | 4,005,114 |
| Executive Vice President, Chief Operating Officer | ||||||||
| Corey Manley | 416,623 | 0 | 1,473,739 | 0 | 499,948 | 0 | 65,700 | 2,456,010 |
| Executive Vice President, Chief Legal and Administrative Officer | ||||||||
| Nchacha Etta | 449,423 | 0 | 0 | 0 | 539,308 | 0 | 996,427 | 1,985,158 |
| Former Executive Vice President, Chief Financial Officer | ||||||||
| H. Baird Radford | 159,519 | 0 | 1,156,572 | 0 | 191,423 | 0 | 6,000 | 1,513,514 |
| Executive Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Randall Lipps | $7,531,852 | $8,174,639 | — | ↓ −642,787 |
| Nnamdi Njoku | 4,005,114 | 2,737,159 | — | ↑ +1,267,955 |
| Corey Manley | 2,456,010 | 2,715,218 | — | ↓ −259,208 |
| Nchacha Etta | 1,985,158 | 3,138,838 | — | ↓ −1,153,680 |
| H. Baird Radford | 1,513,514 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Omnicell's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper OMCL reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses OMCL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named OMCL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| H. Baird Radford | CFO | $1,513,514 |
| Randall Lipps | CEO | $7,531,852 |
| Nchacha Etta | CFO | $1,985,158 |
| Nnamdi Njoku | COO | $4,005,114 |
| Corey Manley | General Counsel | $2,456,010 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Bruce E. Scott | Independent Director | $325,649 |
| Edward P. Bousa | Independent Director | $303,230 |
| Eileen J. Voynick | Independent Director | $318,505 |
| Joanne B. Bauer | Independent Director | $355,141 |
| Kaushik Bobby Ghoshal | Independent Director | $298,148 |
| Mark W. Parrish | Independent Director | $322,366 |
| Mary A. Garrett | Independent Director | $330,141 |
| Robin G. Seim | Lead Independent Director | $323,616 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Corey Manley | EVP&CHIEF LEGAL/ADMIN OFFICER | 2026-05-15 | D | 4,041 | $43 | $174,248 | Common | Form 4 ↗ |
| Brian H. Nutt | VP, Chief Accounting Officer | 2026-05-15 | D | 226 | 43 | 9,745 | Common | Form 4 ↗ |
| Nnamdi Njoku | EVP, Chief Operating Officer | 2026-05-15 | D | 3,660 | 43 | 157,819 | Common | Form 4 ↗ |
| Randall A. Lipps | Director | 2026-05-15 | D | 12,347 | 43 | 532,403 | Common | Form 4 ↗ |
| Corey Manley | EVP&CHIEF LEGAL/ADMIN OFFICER | 2026-05-18 | D | 5,025 | 43 | 217,181 | Common | Form 4 ↗ |
| Nnamdi Njoku | EVP, Chief Operating Officer | 2026-05-18 | D | 3,090 | 43 | 133,550 | Common | Form 4 ↗ |
| Edward P. Bousa | Director | 2026-06-01 | A | 4,603 | 0 | 0 | Common | Form 4 ↗ |
| Mary A. Garrett | Director | 2026-06-01 | A | 5,027 | 0 | 0 | Common | Form 4 ↗ |
| Kaushik Bobby Ghoshal | Director | 2026-06-01 | A | 4,603 | 0 | 0 | Common | Form 4 ↗ |
| Mark W. Parrish | Director | 2026-06-01 | A | 4,845 | 0 | 0 | Common | Form 4 ↗ |
| Joanne B. Bauer | Director | 2026-06-01 | A | 5,027 | 0 | 0 | Common | Form 4 ↗ |
| Bruce E. Scott | Director | 2026-06-01 | A | 4,627 | 0 | 0 | Common | Form 4 ↗ |
| Robin G. Seim | Director | 2026-06-01 | A | 4,845 | 0 | 0 | Common | Form 4 ↗ |
| Eileen J. Voynick | Director | 2026-06-01 | A | 4,785 | 0 | 0 | Common | Form 4 ↗ |
| Nnamdi Njoku | President & COO | 2026-07-01 | A | 12,309 | 0 | 0 | Common | Form 4 ↗ |
| Randall A. Lipps | Director | 2026-07-15 | D | 10,000 | 47 | 470,000 | Common | Form 4 ↗ |
| Randall A. Lipps | Director | 2026-08-15 | D | 12,350 | 37 | 460,655 | Common | Form 4 ↗ |
| Nnamdi Njoku | President & COO | 2026-08-15 | D | 3,670 | 37 | 136,891 | Common | Form 4 ↗ |
| Brian H. Nutt | VP, Chief Accounting Officer | 2026-08-15 | D | 937 | 37 | 34,950 | Common | Form 4 ↗ |
| Corey Manley | EVP&CHIEF LEGAL/ADMIN OFFICER | 2026-08-15 | D | 4,025 | 37 | 150,133 | Common | Form 4 ↗ |
| Nnamdi Njoku | President & COO | 2026-08-17 | D | 3,083 | 37 | 113,609 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Corey Manley | PSU | 2025-03-15 | 11,223 | 22,445 | — | 44,890 | $733,054 |
| Nnamdi Njoku | PSU | 2025-03-15 | 18,705 | 37,409 | — | 74,818 | 1,221,778 |
| Corey Manley | RSU | 2025-03-15 | — | — | 22,445 | — | 740,685 |
| H. Baird Radford | RSU | 2025-11-15 | — | — | 32,932 | — | 1,156,572 |
| Randall Lipps | PSU | 2025-03-15 | 39,747 | 79,494 | — | 158,988 | 2,596,274 |
| Randall Lipps | RSU | 2025-03-15 | — | — | 79,494 | — | 2,623,302 |
| Nnamdi Njoku | RSU | 2025-03-15 | — | — | 37,409 | — | 1,234,497 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Corey Manley | $740,685 | $733,054 | $0 | 49.7% |
| Nnamdi Njoku | 1,234,497 | 1,221,778 | 0 | 49.7% |
| H. Baird Radford | 1,156,572 | 0 | 0 | 0.0% |
| Randall Lipps | 2,623,302 | 2,596,274 | 0 | 49.7% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Nnamdi Njoku | RSU | 40,140 | — | $1,818,342 |
| Nchacha Etta | RSU | 9,463 | — | 428,674 |
| Randall Lipps | PSU | 158,988 | — | 7,202,156 |
| Randall Lipps | RSU | 106,196 | — | 4,810,679 |
| Randall Lipps | RSU | 79,494 | — | 3,601,078 |
| Nnamdi Njoku | PSU | 74,818 | — | 3,389,256 |
| Randall Lipps | RSU | 60,329 | — | 2,732,904 |
| Corey Manley | PSU | 44,890 | — | 2,033,517 |
| Nnamdi Njoku | RSU | 37,409 | — | 1,694,628 |
| H. Baird Radford | RSU | 32,932 | — | 1,491,820 |
| Corey Manley | RSU | 31,649 | — | 1,433,700 |
| Corey Manley | RSU | 22,445 | — | 1,016,759 |
| Corey Manley | RSU | 17,980 | — | 814,494 |
| Nchacha Etta | RSU | 16,657 | — | 754,562 |
| Randall Lipps | RSU | 14,688 | — | 665,366 |
| Corey Manley | RSU | 3,750 | — | 169,875 |
Our executive compensation program is designed to provide our executive officers incentives and rewards, while balancing the short-term and long-term interests of our stockholders with our ability to attract and retain talented executives.
| CEO STI target (% of salary) | 125% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Exequity |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-19 | 35,277,398 | 1,461,980 | 16,442 | 96.02% | Passed |
| 2025 | 2025-05-21 | 35,780,985 | 1,724,508 | 180,671 | 95.4% | Passed |
| 2024 | 2024-05-21 | 36,936,934 | 2,652,637 | 121,211 | 93.3% | Passed |
| 2023 | 2023-05-23 | 36,372,761 | 3,621,541 | 36,343 | 90.94% | Passed |
| 2022 | 2022-05-24 | 37,148,931 | 2,106,001 | 54,571 | 94.64% | Passed |
| 2021 | 2021-05-25 | 35,918,517 | 2,175,281 | 41,883 | 94.29% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-19 | 96.02%a |
| 2025 | 2025-05-21 | 95.4%b |
| 2024 | 2024-05-21 | 93.3%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 70 : 1 |
|---|---|
| CEO total compensation | $7,531,852 |
| Median employee compensation | $106,853 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Joanne B. BauerIndependent · Compensation | $140,000 | $215,141 | $0 | $0 | $0 | $355,141 |
| Mary A. GarrettIndependent · Compensation (Chair) · Corporate Governance (1) | 115,000 | 215,141 | 0 | 0 | 0 | 330,141 |
| Bruce E. ScottIndependent | 117,250 | 208,399 | 0 | 0 | 0 | 325,649 |
| Robin G. SeimIndependent · Lead Independent Director | 116,250 | 207,366 | 0 | 0 | 0 | 323,616 |
| Mark W. ParrishIndependent · Audit (1) · Compensation | 115,000 | 207,366 | 0 | 0 | 0 | 322,366 |
| Eileen J. VoynickIndependent | 113,750 | 204,755 | 0 | 0 | 0 | 318,505 |
| Edward P. BousaIndependent | 106,250 | 196,980 | 0 | 0 | 0 | 303,230 |
| Kaushik Bobby GhoshalIndependent | 103,750 | 194,398 | 0 | 0 | 0 | 298,148 |
| Randall A. LippsEmployee director · Board Chair | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $27,500 |
|---|---|
| Annual equity retainer | $180,000 |
| Per board meeting fee | $27,500 |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 11,000 |
| Stock ownership guideline | $137,500 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $927,250 |
| Equity awards (grant-date value) | $1,649,546 |
| All other compensation | $0 |
| Total cost of the board | $2,576,796 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Omnicell names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Omnicell.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | GoodRx Holdings, Inc. | 2025 | Wendy Barnes | $825,000 | $10,921,182 | $9,000,000 | $0 | $23,367,483 |
| 2 | Nutanix, Inc. | 2025 | Rajiv Ramaswami | 800,000 | 20,750,885 | 0 | 1,015,200 | 22,569,085 |
| 3 | Masimo Corp. | 2025 | Catherine Szyman | 850,048 | 16,388,693 | 1,399,998 | 1,130,000 | 19,797,140 |
| 4 | ACI Worldwide, Inc. | 2025 | Thomas Warsop III | 750,000 | 13,204,027 | 0 | 1,018,875 | 14,999,961 |
| 5 | Evolent Health, Inc. | 2025 | Seth Blackley | 867,068 | 12,699,086 | 0 | 0 | 14,240,154 |
| 6 | HealthEquity, Inc. | 2026 | Scott Cutler | 775,000 | 12,038,563 | 0 | 767,250 | 13,582,105 |
| 7 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 8 | Avanos Medical, Inc. | 2025 | David Pacitti | 751,705 | 7,000,000 | 0 | 1,148,667 | 9,469,803 |
| 9 | Integra LifeSciences Holdings Corporation | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 10 | Integer Holdings Corporation | 2025 | Joseph Dziedzic | 1,235,000 | 5,999,951 | 0 | 1,323,766 | 8,671,332 |
| 11 | Pegasystems Inc. | 2025 | Alan Trefler | 600,000 | 0 | 7,001,532 | 720,000 | 8,332,032 |
| 12 | LivaNova PLC | 2025 | Vladimir Makatsaria | 956,115 | 4,303,092 | 1,374,999 | 1,287,656 | 8,047,217 |
| 13 | Inspire Medical Systems, Inc. | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 14 | CONMED Corporation | 2025 | Patrick Beyer | 891,100 | 2,499,971 | 2,499,977 | 1,129,469 | 7,634,873 |
| 15 | Omnicell | 2025 | Randall Lipps | 846,891 | 5,219,576 | 0 | 1,411,485 | 7,531,852 |
| 16 | Orthofix Medical Inc. | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 17 | Tandem Diabetes Care, Inc. | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 18 | ICU Medical, Inc. | 2025 | Vivek Jain | 775,000 | 4,500,023 | 0 | 1,162,500 | 6,452,042 |
| 19 | Blackbaud Inc | 2025 | Michael Gianoni | 800,031 | 5,206,285 | 0 | 0 | 6,022,250 |
| 20 | Globus Medical, Inc | 2025 | Keith Pfeil | 479,467 | 0 | 2,982,347 | 783,000 | 4,400,159 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Omnicell | 133.3% | RSU 50 · PSU 50 | No | Exequity |
| ACI Worldwide, Inc. | 135.85% | PSU 50 · RSU 50 | No | Compensia, Inc. |
| Avanos Medical, Inc. | 139% | PSU 50 · RSU 25 · Options 25 | No | Meridian Compensation Partners |
| Blackbaud Inc | not disclosed | not disclosed | No | Compensia, Inc. |
| CONMED Corporation | 126.8% | Options 50 · PSU 50 | Yes — rTSR | Compensia, Inc. |
| Evolent Health, Inc. | 75% | PSU 70 · RSU 30 | No | Exequity |
| Globus Medical, Inc | 102% | Options 100 | not disclosed | FW Cook |
| GoodRx Holdings, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| HealthEquity, Inc. | 99% | PSU 60 · RSU 40 | Yes | Semler Brossy |
| ICU Medical, Inc. | 150% | PSU 50 · RSU 50 | No | Compensia |
| Inspire Medical Systems, Inc. | 111.4% | PSU 50 · RSU 50 | No | Aon |
| Integer Holdings Corporation | 85.75% | PSU 66 · RSU 34 | Yes — Relative TSR versus peer group | FW Cook |
| Integra LifeSciences Holdings Corporation | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| LivaNova PLC | 122.4% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Masimo Corp. | not disclosed | not disclosed | not disclosed | FW Cook |
| Nutanix, Inc. | 126.9% | RSU 50 · PSU 50 | Yes — Relative TSR vs Nasdaq Composite Index | Compensia, Inc. |
| Orthofix Medical Inc. | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| Pegasystems Inc. | 120% | not disclosed | No | not disclosed |
| Tandem Diabetes Care, Inc. | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Randall Lipps | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “2025 SUMMARY COMPENSATION TABLE” · page 42. As printed: 7,531,852. Filing ↗machine: r1 · c47 · span 668949–668958 |
| 2 | Section 01, Nnamdi Njoku | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “2025 SUMMARY COMPENSATION TABLE” · page 42. As printed: 4,005,114. Filing ↗machine: r5 · c47 · span 688371–688380 |
| 3 | Section 01, Corey Manley | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “2025 SUMMARY COMPENSATION TABLE” · page 42. As printed: 2,456,010. Filing ↗machine: r7 · c47 · span 698277–698286 |
| 4 | Section 01, Nchacha Etta | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “2025 SUMMARY COMPENSATION TABLE” · page 42. As printed: 1,985,158. Filing ↗machine: r10 · c47 · span 713919–713928 |
| 5 | Section 01, H. Baird Radford | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “2025 SUMMARY COMPENSATION TABLE” · page 42. As printed: 1,513,514. Filing ↗machine: r4 · c47 · span 682944–682953 |
| 6 | Section 03, Corey Manley PSU | DEF 14A | 1900-01-01 | 0001104659-26-042631 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 798142–798149 |
| 7 | Section 03, Nnamdi Njoku PSU | DEF 14A | 1900-01-01 | 0001104659-26-042631 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 781659–781668 |
| 8 | Section 03, Corey Manley RSU | DEF 14A | 1900-01-01 | 0001104659-26-042631 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 805133–805140 |
| 9 | Section 03, H. Baird Radford RSU | DEF 14A | 1900-01-01 | 0001104659-26-042631 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 770378–770387 |
| 10 | Section 03, Randall Lipps PSU | DEF 14A | 1900-01-01 | 0001104659-26-042631 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 753718–753727 |
| 11 | Section 03, Randall Lipps RSU | DEF 14A | 1900-01-01 | 0001104659-26-042631 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 758962–758971 |
| 12 | Section 03, Nnamdi Njoku RSU | DEF 14A | 1900-01-01 | 0001104659-26-042631 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 786887–786896 |
| 13 | Section 07, pay ratio | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “CEO Pay Ratio”. As printed: 70 : 1. Filing ↗ |
| 14 | Section 08, Joanne B. Bauer | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “Director Compensation”. As printed: 355,141. Filing ↗machine: span 378575–378582 |
| 15 | Section 08, Mary A. Garrett | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “Director Compensation”. As printed: 330,141. Filing ↗machine: span 384804–384811 |
| 16 | Section 08, Bruce E. Scott | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “Director Compensation”. As printed: 325,649. Filing ↗machine: span 394154–394161 |
| 17 | Section 08, Robin G. Seim | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “Director Compensation”. As printed: 323,616. Filing ↗machine: span 397279–397286 |
| 18 | Section 08, Mark W. Parrish | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “Director Compensation”. As printed: 322,366. Filing ↗machine: span 391053–391060 |
| 19 | Section 08, Eileen J. Voynick | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “Director Compensation”. As printed: 318,505. Filing ↗machine: span 400383–400390 |
| 20 | Section 08, Edward P. Bousa | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “Director Compensation”. As printed: 303,230. Filing ↗machine: span 381677–381684 |
| 21 | Section 08, Kaushik Bobby Ghoshal | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “Director Compensation”. As printed: 298,148. Filing ↗machine: span 387926–387933 |
| 22 | Section 08, Randall A. Lipps | DEF 14A | 2026-04-13 | 0001104659-26-042631 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 23 | Section 02, Corey Manley 2026-05-15 | Form 4 | 2026-05-19 | 0001928727-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Brian H. Nutt 2026-05-15 | Form 4 | 2026-05-19 | 0001520961-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Nnamdi Njoku 2026-05-15 | Form 4 | 2026-05-19 | 0002034946-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Randall A. Lipps 2026-05-15 | Form 4 | 2026-05-19 | 0001227556-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Corey Manley 2026-05-18 | Form 4 | 2026-05-19 | 0001928727-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Nnamdi Njoku 2026-05-18 | Form 4 | 2026-05-19 | 0002034946-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Edward P. Bousa 2026-06-01 | Form 4 | 2026-06-03 | 0001452605-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Mary A. Garrett 2026-06-01 | Form 4 | 2026-06-03 | 0001663588-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Kaushik Bobby Ghoshal 2026-06-01 | Form 4 | 2026-06-03 | 0001881922-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Mark W. Parrish 2026-06-01 | Form 4 | 2026-06-03 | 0001236452-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Joanne B. Bauer 2026-06-01 | Form 4 | 2026-06-03 | 0001359343-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Bruce E. Scott 2026-06-01 | Form 4 | 2026-06-03 | 0001776980-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Robin G. Seim 2026-06-01 | Form 4 | 2026-06-03 | 0001351911-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Eileen J. Voynick 2026-06-01 | Form 4 | 2026-06-03 | 0001683609-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Nnamdi Njoku 2026-07-01 | Form 4 | 2026-07-06 | 0002034946-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Randall A. Lipps 2026-07-15 | Form 4 | 2026-07-17 | 0001227556-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Randall A. Lipps 2026-08-15 | Form 4 | 2026-08-18 | 0001227556-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Nnamdi Njoku 2026-08-15 | Form 4 | 2026-08-18 | 0002034946-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Brian H. Nutt 2026-08-15 | Form 4 | 2026-08-18 | 0001520961-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Corey Manley 2026-08-15 | Form 4 | 2026-08-18 | 0001928727-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Nnamdi Njoku 2026-08-17 | Form 4 | 2026-08-18 | 0002034946-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 06, 2026 vote | Form 8-K | 2026-05-26 | 0001104659-26-066316 | Item 5.07 · say-on-pay result. As reported: 96.02% (votes for as printed: 35,277,398). Filing ↗ |
| 45 | Section 06, 2025 vote | Form 8-K | 2025-05-23 | 0001104659-25-052464 | Item 5.07 · say-on-pay result. As reported: 95.4% (votes for as printed: 35,780,985). Filing ↗ |
| 46 | Section 06, 2024 vote | Form 8-K | 2024-05-24 | 0001104659-24-065130 | Item 5.07 · say-on-pay result. As reported: 93.3% (votes for as printed: 36,936,934). Filing ↗ |
| 47 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 48 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 49 | Section 09b board cost (computed) | Computed | — | — | Cash 927,250 + equity 1,649,546 + all other 0 = 2,576,796, summed across the director compensation table rows.machine: formula: Σ = 2,576,796 |
| 50 | GoodRx Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001809519-26-000091 | CEO total compensation as printed in GoodRx Holdings, Inc.'s own proxy. As printed: 23,367,483. Filing ↗machine: r2 · c16 · span 1286734–1286744 |
| 51 | Nutanix, Inc., Section 10b CEO total | DEF 14A | 2025-10-22 | 0001193125-25-246962 | CEO total compensation as printed in Nutanix, Inc.'s own proxy. As printed: 22,569,085. Filing ↗machine: r4 · c28 · span 1819325–1819335 |
| 52 | Masimo Corp., Section 10b CEO total | 10-K | 2026-05-01 | 0001104659-26-054180 | CEO total compensation as printed in Masimo Corp.'s own proxy. As printed: 19,797,140. Filing ↗machine: r4 · c22 · span 477159–477169 |
| 53 | ACI Worldwide, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001193125-26-162572 | CEO total compensation as printed in ACI Worldwide, Inc.'s own proxy. As printed: 14,999,961. Filing ↗machine: r6 · c34 · span 887084–887094 |
| 54 | Evolent Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177267 | CEO total compensation as printed in Evolent Health, Inc.'s own proxy. As printed: 14,240,154. Filing ↗machine: r3 · c20 · span 908544–908555 |
| 55 | HealthEquity, Inc., Section 10b CEO total | DEF 14A | 2026-05-13 | 0001428336-26-000022 | CEO total compensation as printed in HealthEquity, Inc.'s own proxy. As printed: 13,582,105. Filing ↗machine: r3 · c21 · span 892475–892485 |
| 56 | Haemonetics Corporation, Section 10b CEO total | DEF 14A | 2026-06-09 | 0000313143-26-000074 | CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183 |
| 57 | Avanos Medical, Inc., Section 10b CEO total | DEF 14A | 2026-03-12 | 0001104659-26-027106 | CEO total compensation as printed in Avanos Medical, Inc.'s own proxy. As printed: 9,469,803. Filing ↗machine: r1 · c53 · span 1674377–1674386 |
| 58 | Integra LifeSciences Holdings Corporation, Section 10b CEO total | DEF 14A | 2026-04-06 | 0000917520-26-000015 | CEO total compensation as printed in Integra LifeSciences Holdings Corporation's own proxy. As printed: 9,375,551. Filing ↗machine: r2 · c30 · span 880204–880213 |
| 59 | Integer Holdings Corporation, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001114483-26-000009 | CEO total compensation as printed in Integer Holdings Corporation's own proxy. As printed: 8,671,332. Filing ↗machine: t48 · r17 · c21 · span 738226–738235 |
| 60 | Pegasystems Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001013857-26-000031 | CEO total compensation as printed in Pegasystems Inc.'s own proxy. As printed: 8,332,032. Filing ↗machine: span 334047–334056 |
| 61 | LivaNova PLC, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-050937 | CEO total compensation as printed in LivaNova PLC's own proxy. As printed: 8,047,217. Filing ↗machine: t117 · r3 · c50 · span 1095329–1095338 |
| 62 | Inspire Medical Systems, Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001140361-26-010490 | CEO total compensation as printed in Inspire Medical Systems, Inc.'s own proxy. As printed: 7,711,784. Filing ↗machine: r2 · c25 · span 1164868–1164877 |
| 63 | CONMED Corporation, Section 10b CEO total | DEF 14A | 2026-04-07 | 0000816956-26-000047 | CEO total compensation as printed in CONMED Corporation's own proxy. As printed: 7,634,873. Filing ↗machine: r3 · c27 · span 1186564–1186573 |
| 64 | Omnicell (subject), Section 10b CEO total | DEF 14A | 2026-04-13 | 0001104659-26-042631 | CEO total compensation as printed in Omnicell's own proxy. As printed: 7,531,852. Filing ↗machine: r1 · c47 · span 668949–668958 |
| 65 | Orthofix Medical Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191716 | CEO total compensation as printed in Orthofix Medical Inc.'s own proxy. As printed: 7,310,039. Filing ↗machine: t96 · r4 · c16 · span 1472329–1472338 |
| 66 | Tandem Diabetes Care, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001438133-26-000034 | CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. Filing ↗machine: r3 · c27 · span 866963–866972 |
| 67 | ICU Medical, Inc., Section 10b CEO total | DEF 14A | 2026-04-02 | 0000883984-26-000019 | CEO total compensation as printed in ICU Medical, Inc.'s own proxy. As printed: 6,452,042. Filing ↗machine: r2 · c24 · span 432290–432299 |
| 68 | Blackbaud Inc, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001280058-26-000009 | CEO total compensation as printed in Blackbaud Inc's own proxy. As printed: 6,022,250. Filing ↗machine: span 1051214–1051223 |
| 69 | Globus Medical, Inc, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027196 | CEO total compensation as printed in Globus Medical, Inc's own proxy. As printed: 4,400,159. Filing ↗machine: r5 · c21 · span 344690–344699 |
| 70 | Section 10a, LivaNova PLC reciprocity | DEF 14A | — | 0001104659-26-050937 | LivaNova PLC's most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 71 | Section 10a, GoodRx Holdings, Inc. reciprocity | DEF 14A | — | 0001809519-26-000091 | GoodRx Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 72 | Section 10a, ICU Medical, Inc. reciprocity | DEF 14A | — | 0000883984-26-000019 | ICU Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 73 | Section 10a, Masimo Corp. reciprocity | DEF 14A | — | 0001104659-26-054180 | Masimo Corp.'s most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 74 | Section 10a, Haemonetics Corporation reciprocity | DEF 14A | — | 0000313143-26-000074 | Haemonetics Corporation's most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 75 | Section 10a, Avanos Medical, Inc. reciprocity | DEF 14A | — | 0001104659-26-027106 | Avanos Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 76 | Section 10a, Pegasystems Inc. reciprocity | DEF 14A | — | 0001013857-26-000031 | Pegasystems Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 77 | Section 10a, Blackbaud Inc reciprocity | DEF 14A | — | 0001280058-26-000009 | Blackbaud Inc's most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 78 | Section 10a, Tandem Diabetes Care, Inc. reciprocity | DEF 14A | — | 0001438133-26-000034 | Tandem Diabetes Care, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 79 | Section 10a, Integra LifeSciences Holdings Corporation reciprocity | DEF 14A | — | 0000917520-26-000015 | Integra LifeSciences Holdings Corporation's most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 80 | Section 10a, HealthEquity, Inc. reciprocity | DEF 14A | — | 0001428336-26-000022 | HealthEquity, Inc. names Omnicell in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 81 | Section 10a, Nutanix, Inc. reciprocity | DEF 14A | — | 0001193125-25-246962 | Nutanix, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 82 | Section 10a, CONMED Corporation reciprocity | DEF 14A | — | 0000816956-26-000047 | CONMED Corporation's most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 83 | Section 10a, Inspire Medical Systems, Inc. reciprocity | DEF 14A | — | 0001140361-26-010490 | Inspire Medical Systems, Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 84 | Section 10a, Orthofix Medical Inc. reciprocity | DEF 14A | — | 0001193125-26-191716 | Orthofix Medical Inc.'s most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
| 85 | Section 10a, Evolent Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-177267 | Evolent Health, Inc. names Omnicell in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 86 | Section 10a, Integer Holdings Corporation reciprocity | DEF 14A | — | 0001114483-26-000009 | Integer Holdings Corporation's most recent proxy was read; its disclosed peer group does not include Omnicell. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.